Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Rallybio Corporation RLYB
$5.15
+$0.03 (0.59%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
211697000.00000000
-
week52high
15.89
-
week52low
4.15
-
Revenue
0
-
P/E TTM
-3
-
Beta
0.00000000
-
EPS
-2.08000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 04:00
Описание компании
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| JMP Securities | Market Outperform | Market Outperform | 09 авг 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 16 мар 2022 г. |
| JMP Securities | Market Outperform | 22 февр 2022 г. | |
| Jefferies | Buy | 23 авг 2021 г. | |
| Evercore ISI Group | Outperform | 23 авг 2021 г. | |
| JP Morgan | Overweight | 09 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Lieber Jonathan I | A | 240000 | 240000 | 01 февр 2023 г. |
| HUNT RONALD | A | 11099 | 11099 | 03 янв 2023 г. |
| Chung Wendy | A | 9482 | 9482 | 03 янв 2023 г. |
| PARMAR KUSH | A | 10344 | 10344 | 03 янв 2023 г. |
| Liu Hui | A | 10237 | 10237 | 03 янв 2023 г. |
| VIKING GLOBAL INVESTORS LP | A | 3333388 | 3333388 | 15 ноя 2022 г. |
| Chung Wendy | A | 26880 | 26880 | 01 авг 2022 г. |
| 5AM Opportunities I, L.P. | D | 2478969 | 99671 | 03 июн 2022 г. |
| 5AM Opportunities I, L.P. | D | 1251755 | 50329 | 03 июн 2022 г. |
| PARMAR KUSH | D | 1251755 | 50329 | 03 июн 2022 г. |
Новостная лента
Rallybio to Present at the JMP Securities Hematology and Oncology Summit
Business Wire
29 ноя 2022 г. в 08:00
NEW HAVEN, Conn.--( BUSINESS WIRE )--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 7, 2022, at 1:40 p.m. ET.
Rallybio to Present at Upcoming Investor Conferences in November
Business Wire
11 ноя 2022 г. в 08:00
NEW HAVEN, Conn.--( BUSINESS WIRE )--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences:
Rallybio to Present at the 2022 Wells Fargo Healthcare Conference
Business Wire
31 авг 2022 г. в 08:00
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 3:10 p.m. ET in Everett, MA. A live webcast of the fireside chat will be accessible through the E